表紙：敗血症診断の世界市場 - 市場機会分析および産業予測：製品別、技術別、手法別、使用別、病原体別（2020年～2030年）

市場調査レポート

商品コード

1097666

敗血症診断の世界市場 - 市場機会分析および産業予測：製品別、技術別、手法別、使用別、病原体別（2020年～2030年）

Global Sepsis Diagnostic Market By Product, By Technology, By Method, By Usability, By Pathogen : Global Opportunity Analysis and Industry Forecast, 2020-2030

出版日: 2022年04月01日 | 発行: Allied Market Research

| ページ情報: 英文 205 Pages | 納期: 2～3営業日

価格

PDF (Single User License)

USD 5,730 898,234円

レポートPDFを1つのPCでご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回だけ可能です。印刷したレポートの利用もPDFのライセンス保持者になります。回覧のための複製も原則NGです。

PDF (5-user License)

USD 6,450 1,011,102円

レポートPDFを5名でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回可能です。印刷したレポートの利用もPDFのライセンス保持者5名となります。

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 9,600 1,504,896円

レポートPDFとExcel定量データをひとつの企業、及びその子会社でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFとExcelの保存、表示、利用が可能です。PDFとExcel内のテキスト等のコピー＆ペーストは可能です。PDFとExcelの印刷回数の制限はありません。印刷したレポートの利用は企業、及びその子会社内にて共有可能です。無料でレポートのアップデートがご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の敗血症診断の市場規模は、2020年に5億6,949万米ドルとなり、2021年～2030年の間にCAGR7.8％で成長し、2030年までに12億758万米ドルに達すると予測されます。

市場を牽引するのは、敗血症関連の研究活動に対する政府資金の増加や感染症の流行です。また、敗血症の負担の増加や世界の高齢者人口の増加が市場の成長を後押ししています。しかし、自動診断装置のコストが高いことが市場成長の妨げになると予想されます。一方、敗血症の早期診断のための迅速診断/ポイントオブケア技術の開発は、予測期間中に市場企業に有利な機会を提供すると予想されます。

当レポートでは、世界の敗血症診断市場を調査分析し、市場概要、セグメント別・地域別の市場分析、競合情勢、主要企業のプロファイルなどの情報を提供しています。

概要
- 市場規模と予測
血液培地
- 主要な市場動向、成長要因および機会
- 市場規模と予測：地域別
- 市場分析：国別
機器
- 主要な市場動向、成長要因および機会
- 市場規模と予測：地域別
- 市場分析：国別
アッセイキット・試薬
- 主要な市場動向、成長要因および機会
- 市場規模と予測：地域別
- 市場分析：国別
ソフトウェア
- 主要な市場動向、成長要因および機会
- 市場規模と予測：地域別
- 市場分析：国別

第5章世界の敗血症診断市場：技術別

概要
- 市場規模と予測
微生物学
- 主要な市場動向、成長要因および機会
- 市場規模と予測：地域別
- 市場分析：国別
分子診断
- 主要な市場動向、成長要因および機会
- 市場規模と予測：地域別
- 市場分析：国別
免疫学的検査
- 主要な市場動向、成長要因および機会
- 市場規模と予測：地域別
- 市場分析：国別
フローサイトメトリー
- 主要な市場動向、成長要因および機会
- 市場規模と予測：地域別
- 市場分析：国別

第6章世界の敗血症診断市場：手法別

概要
- 市場規模と予測
従来の診断
- 主要な市場動向、成長要因および機会
- 市場規模と予測：地域別
- 市場分析：国別
自動診断
- 主要な市場動向、成長要因および機会
- 市場規模と予測：地域別
- 市場分析：国別

第7章世界の敗血症診断市場：使用別

概要
- 市場規模と予測
臨床検査
- 主要な市場動向、成長要因および機会
- 市場規模と予測：地域別
- 市場分析：国別
ポイントオブケア検査
- 主要な市場動向、成長要因および機会
- 市場規模と予測：地域別
- 市場分析：国別

第8章世界の敗血症診断市場：病原体別

概要
- 市場規模と予測
細菌性敗血症
- 主要な市場動向、成長要因および機会
- 市場規模と予測：地域別
- 市場分析：国別
真菌性敗血症
- 主要な市場動向、成長要因および機会
- 市場規模と予測：地域別
- 市場分析：国別
その他
- 主要な市場動向、成長要因および機会
- 市場規模と予測：地域別
- 市場分析：国別

第9章世界の敗血症診断市場：地域別

概要
- 市場規模と予測
北米
- 主な動向と機会
- 北米市場の規模と予測：製品別
- 北米市場の規模と予測：技術別
- 北米市場の規模と予測：手法別
- 北米市場の規模と予測：使用別
- 北米市場の規模と予測：病原体別
- 北米市場の規模と予測：国別
  - 米国
  - カナダ
  - メキシコ
欧州
- 主な動向と機会
- 欧州市場の規模と予測：製品別
- 欧州市場の規模と予測：技術別
- 欧州市場の規模と予測：手法別
- 欧州市場の規模と予測：使用別
- 欧州市場の規模と予測：病原体別
- 欧州市場の規模と予測：国別
  - ドイツ
  - フランス
  - 英国
  - イタリア
  - スペイン
  - その他欧州
アジア太平洋
- 主な動向と機会
- アジア太平洋市場の規模と予測：製品別
- アジア太平洋市場の規模と予測：技術別
- アジア太平洋市場の規模と予測：手法別
- アジア太平洋市場の規模と予測：使用別
- アジア太平洋市場の規模と予測：病原体別
- アジア太平洋市場の規模と予測：国別
  - 日本
  - 中国
  - オーストラリア
  - インド
  - 韓国
  - その他アジア太平洋
ラテンアメリカ・中東・アフリカ
- 主な動向と機会
- ラテンアメリカ・中東・アフリカ市場の規模と予測：製品別
- ラテンアメリカ・中東・アフリカ市場の規模と予測：技術別
- ラテンアメリカ・中東・アフリカ市場の規模と予測：手法別
- ラテンアメリカ・中東・アフリカ市場の規模と予測：使用別
- ラテンアメリカ・中東・アフリカ市場の規模と予測：病原体別
- ラテンアメリカ・中東・アフリカ市場の規模と予測：国別
  - ブラジル
  - サウジアラビア
  - 南アフリカ
  - その他ラテンアメリカ・中東・アフリカ

第10章企業情勢

イントロダクション
主な成功戦略
主要10社の製品マッピング
競合ダッシュボード
競合ヒートマップ
主な発展

第11章企業プロファイル

会社概要
会社のスナップショット
事業セグメントの運営
製品ポートフォリオ
業績
重要な戦略的動きと開発

BioMerieux SA
- 会社概要
- 会社のスナップショット
- 事業セグメントの運営
- 製品ポートフォリオ
- 業績
- 重要な戦略的動きと開発
Thermo Fisher Scientific Inc.
- 会社概要
- 会社のスナップショット
- 事業セグメントの運営
- 製品ポートフォリオ
- 業績
- 重要な戦略的動きと開発
Abbott Laboratories, Inc.
- 会社概要
- 会社のスナップショット
- 事業セグメントの運営
- 製品ポートフォリオ
- 業績
- 重要な戦略的動きと開発
Becton, Dickinson and Company
- 会社概要
- 会社のスナップショット
- 事業セグメントの運営
- 製品ポートフォリオ
- 業績
- 重要な戦略的動きと開発
Broker Corporation
- 会社概要
- 会社のスナップショット
- 事業セグメントの運営
- 製品ポートフォリオ
- 業績
- 重要な戦略的動きと開発
Beckman Coulter, Inc.
- 会社概要
- 会社のスナップショット
- 事業セグメントの運営
- 製品ポートフォリオ
- 業績
- 重要な戦略的動きと開発
T2 Biosystems, Inc
- 会社概要
- 会社のスナップショット
- 事業セグメントの運営
- 製品ポートフォリオ
- 業績
- 重要な戦略的動きと開発
Nanosphere, Inc.
- 会社概要
- 会社のスナップショット
- 事業セグメントの運営
- 製品ポートフォリオ
- 業績
- 重要な戦略的動きと開発
Hoffmann-LA Roche Ltd
- 会社概要
- 会社のスナップショット
- 事業セグメントの運営
- 製品ポートフォリオ
- 業績
- 重要な戦略的動きと開発
Danaher Corporation
- 会社概要
- 会社のスナップショット
- 事業セグメントの運営
- 製品ポートフォリオ
- 業績
- 重要な戦略的動きと開発

図表

LIST OF TABLES

TABLE 1. GLOBAL GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 2. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR BLOOD CULTURE MEDIA, BY REGION , 2020-2030,($MILLION)
TABLE 3. GLOBAL SEPSIS DIAGNOSTIC MARKET BLOOD CULTURE MEDIA BY COUNTRY, 2020-2030,($MILLION)
TABLE 4. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR INSTRUMENTS, BY REGION , 2020-2030,($MILLION)
TABLE 5. GLOBAL SEPSIS DIAGNOSTIC MARKET INSTRUMENTS BY COUNTRY, 2020-2030,($MILLION)
TABLE 6. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR ASSAY KITS & REAGENTS, BY REGION , 2020-2030,($MILLION)
TABLE 7. GLOBAL SEPSIS DIAGNOSTIC MARKET ASSAY KITS & REAGENTS BY COUNTRY, 2020-2030,($MILLION)
TABLE 8. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR SOFTWARE, BY REGION , 2020-2030,($MILLION)
TABLE 9. GLOBAL SEPSIS DIAGNOSTIC MARKET SOFTWARE BY COUNTRY, 2020-2030,($MILLION)
TABLE 10. GLOBAL GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
TABLE 11. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR MICROBIOLOGY, BY REGION , 2020-2030,($MILLION)
TABLE 12. GLOBAL SEPSIS DIAGNOSTIC MARKET MICROBIOLOGY BY COUNTRY, 2020-2030,($MILLION)
TABLE 13. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR MOLECULAR DIAGNOSTICS, BY REGION , 2020-2030,($MILLION)
TABLE 14. GLOBAL SEPSIS DIAGNOSTIC MARKET MOLECULAR DIAGNOSTICS BY COUNTRY, 2020-2030,($MILLION)
TABLE 15. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR IMMUNOASSAYS, BY REGION , 2020-2030,($MILLION)
TABLE 16. GLOBAL SEPSIS DIAGNOSTIC MARKET IMMUNOASSAYS BY COUNTRY, 2020-2030,($MILLION)
TABLE 17. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR FLOW CYTOMETRY, BY REGION , 2020-2030,($MILLION)
TABLE 18. GLOBAL SEPSIS DIAGNOSTIC MARKET FLOW CYTOMETRY BY COUNTRY, 2020-2030,($MILLION)
TABLE 19. GLOBAL GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD, 2020-2030,($MILLION)
TABLE 20. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR CONVENTIONAL DIAGNOSTICS, BY REGION , 2020-2030,($MILLION)
TABLE 21. GLOBAL SEPSIS DIAGNOSTIC MARKET CONVENTIONAL DIAGNOSTICS BY COUNTRY, 2020-2030,($MILLION)
TABLE 22. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR AUTOMATED DIAGNOSTICS, BY REGION , 2020-2030,($MILLION)
TABLE 23. GLOBAL SEPSIS DIAGNOSTIC MARKET AUTOMATED DIAGNOSTICS BY COUNTRY, 2020-2030,($MILLION)
TABLE 24. GLOBAL GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY, 2020-2030,($MILLION)
TABLE 25. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR LABORATORY TESTING, BY REGION , 2020-2030,($MILLION)
TABLE 26. GLOBAL SEPSIS DIAGNOSTIC MARKET LABORATORY TESTING BY COUNTRY, 2020-2030,($MILLION)
TABLE 27. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR POINT-OF-CARE TESTING, BY REGION , 2020-2030,($MILLION)
TABLE 28. GLOBAL SEPSIS DIAGNOSTIC MARKET POINT-OF-CARE TESTING BY COUNTRY, 2020-2030,($MILLION)
TABLE 29. GLOBAL GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN, 2020-2030,($MILLION)
TABLE 30. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR BACTERIAL SEPSIS, BY REGION , 2020-2030,($MILLION)
TABLE 31. GLOBAL SEPSIS DIAGNOSTIC MARKET BACTERIAL SEPSIS BY COUNTRY, 2020-2030,($MILLION)
TABLE 32. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR FUNGAL SEPSIS, BY REGION , 2020-2030,($MILLION)
TABLE 33. GLOBAL SEPSIS DIAGNOSTIC MARKET FUNGAL SEPSIS BY COUNTRY, 2020-2030,($MILLION)
TABLE 34. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($MILLION)
TABLE 35. GLOBAL SEPSIS DIAGNOSTIC MARKET OTHERS BY COUNTRY, 2020-2030,($MILLION)
TABLE 36. GLOBAL SEPSIS DIAGNOSTIC MARKET, BY REGION, 2020-2030,($MILLION)
TABLE 37. NORTH AMERICA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 38. NORTH AMERICA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
TABLE 39. NORTH AMERICA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD, 2020-2030,($MILLION)
TABLE 40. NORTH AMERICA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY, 2020-2030,($MILLION)
TABLE 41. NORTH AMERICA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN, 2020-2030,($MILLION)
TABLE 42. NORTH AMERICA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 43. U.S. GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 44. U.S. GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 45. U.S. GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
TABLE 46. U.S. GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
TABLE 47. U.S. GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
TABLE 48. CANADA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 49. CANADA GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 50. CANADA GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
TABLE 51. CANADA GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
TABLE 52. CANADA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
TABLE 53. MEXICO GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 54. MEXICO GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 55. MEXICO GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
TABLE 56. MEXICO GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
TABLE 57. MEXICO GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
TABLE 58. EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 59. EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
TABLE 60. EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD, 2020-2030,($MILLION)
TABLE 61. EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY, 2020-2030,($MILLION)
TABLE 62. EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN, 2020-2030,($MILLION)
TABLE 63. EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 64. GERMANY GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 65. GERMANY GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 66. GERMANY GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
TABLE 67. GERMANY GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
TABLE 68. GERMANY GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
TABLE 69. FRANCE GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 70. FRANCE GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 71. FRANCE GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
TABLE 72. FRANCE GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
TABLE 73. FRANCE GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
TABLE 74. U.K. GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 75. U.K. GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 76. U.K. GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
TABLE 77. U.K. GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
TABLE 78. U.K. GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
TABLE 79. ITALY GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 80. ITALY GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 81. ITALY GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
TABLE 82. ITALY GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
TABLE 83. ITALY GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
TABLE 84. SPAIN GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 85. SPAIN GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 86. SPAIN GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
TABLE 87. SPAIN GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
TABLE 88. SPAIN GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
TABLE 89. REST OF EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 90. REST OF EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 91. REST OF EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
TABLE 92. REST OF EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
TABLE 93. REST OF EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
TABLE 94. ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 95. ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
TABLE 96. ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD, 2020-2030,($MILLION)
TABLE 97. ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY, 2020-2030,($MILLION)
TABLE 98. ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN, 2020-2030,($MILLION)
TABLE 99. ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 100. JAPAN GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 101. JAPAN GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 102. JAPAN GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
TABLE 103. JAPAN GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
TABLE 104. JAPAN GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
TABLE 105. CHINA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 106. CHINA GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 107. CHINA GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
TABLE 108. CHINA GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
TABLE 109. CHINA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
TABLE 110. AUSTRALIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 111. AUSTRALIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 112. AUSTRALIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
TABLE 113. AUSTRALIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
TABLE 114. AUSTRALIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
TABLE 115. INDIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 116. INDIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 117. INDIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
TABLE 118. INDIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
TABLE 119. INDIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
TABLE 120. SOUTH KOREA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 121. SOUTH KOREA GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 122. SOUTH KOREA GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
TABLE 123. SOUTH KOREA GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
TABLE 124. SOUTH KOREA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
TABLE 125. REST OF ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 126. REST OF ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 127. REST OF ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
TABLE 128. REST OF ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
TABLE 129. REST OF ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
TABLE 130. LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 131. LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
TABLE 132. LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD, 2020-2030,($MILLION)
TABLE 133. LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY, 2020-2030,($MILLION)
TABLE 134. LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN, 2020-2030,($MILLION)
TABLE 135. LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 136. BRAZIL GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 137. BRAZIL GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 138. BRAZIL GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
TABLE 139. BRAZIL GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
TABLE 140. BRAZIL GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
TABLE 141. SAUDI ARABIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 142. SAUDI ARABIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 143. SAUDI ARABIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
TABLE 144. SAUDI ARABIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
TABLE 145. SAUDI ARABIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
TABLE 146. SOUTH AFRICA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 147. SOUTH AFRICA GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 148. SOUTH AFRICA GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
TABLE 149. SOUTH AFRICA GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
TABLE 150. SOUTH AFRICA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
TABLE 151. REST OF LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 152. REST OF LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 153. REST OF LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
TABLE 154. REST OF LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
TABLE 155. REST OF LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
TABLE 156.: COMPANY SNAPSHOT
TABLE 157.: OPERATING SEGMENTS
TABLE 158.: PRODUCT PORTFOLIO
TABLE 159.: NET SALES,
TABLE 160.: KEY STRATERGIES
TABLE 161.BIOMERIEUX SA: COMPANY SNAPSHOT
TABLE 162.BIOMERIEUX SA: OPERATING SEGMENTS
TABLE 163.BIOMERIEUX SA: PRODUCT PORTFOLIO
TABLE 164.BIOMERIEUX SA: NET SALES,
TABLE 165.BIOMERIEUX SA: KEY STRATERGIES
TABLE 166.THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
TABLE 167.THERMO FISHER SCIENTIFIC INC.: OPERATING SEGMENTS
TABLE 168.THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
TABLE 169.THERMO FISHER SCIENTIFIC INC.: NET SALES,
TABLE 170.THERMO FISHER SCIENTIFIC INC.: KEY STRATERGIES
TABLE 171.ABBOTT LABORATORIES, INC.: COMPANY SNAPSHOT
TABLE 172.ABBOTT LABORATORIES, INC.: OPERATING SEGMENTS
TABLE 173.ABBOTT LABORATORIES, INC.: PRODUCT PORTFOLIO
TABLE 174.ABBOTT LABORATORIES, INC.: NET SALES,
TABLE 175.ABBOTT LABORATORIES, INC.: KEY STRATERGIES
TABLE 176.BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
TABLE 177.BECTON, DICKINSON AND COMPANY: OPERATING SEGMENTS
TABLE 178.BECTON, DICKINSON AND COMPANY: PRODUCT PORTFOLIO
TABLE 179.BECTON, DICKINSON AND COMPANY: NET SALES,
TABLE 180.BECTON, DICKINSON AND COMPANY: KEY STRATERGIES
TABLE 181.BRUKER CORPORATION: COMPANY SNAPSHOT
TABLE 182.BRUKER CORPORATION: OPERATING SEGMENTS
TABLE 183.BRUKER CORPORATION: PRODUCT PORTFOLIO
TABLE 184.BRUKER CORPORATION: NET SALES,
TABLE 185.BRUKER CORPORATION: KEY STRATERGIES
TABLE 186.BECKMAN COULTER, INC.: COMPANY SNAPSHOT
TABLE 187.BECKMAN COULTER, INC.: OPERATING SEGMENTS
TABLE 188.BECKMAN COULTER, INC.: PRODUCT PORTFOLIO
TABLE 189.BECKMAN COULTER, INC.: NET SALES,
TABLE 190.BECKMAN COULTER, INC.: KEY STRATERGIES
TABLE 191.T2 BIOSYSTEMS, INC: COMPANY SNAPSHOT
TABLE 192.T2 BIOSYSTEMS, INC: OPERATING SEGMENTS
TABLE 193.T2 BIOSYSTEMS, INC: PRODUCT PORTFOLIO
TABLE 194.T2 BIOSYSTEMS, INC: NET SALES,
TABLE 195.T2 BIOSYSTEMS, INC: KEY STRATERGIES
TABLE 196.NANOSPHERE, INC.: COMPANY SNAPSHOT
TABLE 197.NANOSPHERE, INC.: OPERATING SEGMENTS
TABLE 198.NANOSPHERE, INC.: PRODUCT PORTFOLIO
TABLE 199.NANOSPHERE, INC.: NET SALES,
TABLE 200.NANOSPHERE, INC.: KEY STRATERGIES
TABLE 201.HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
TABLE 202.HOFFMANN-LA ROCHE LTD: OPERATING SEGMENTS
TABLE 203.HOFFMANN-LA ROCHE LTD: PRODUCT PORTFOLIO
TABLE 204.HOFFMANN-LA ROCHE LTD: NET SALES,
TABLE 205.HOFFMANN-LA ROCHE LTD: KEY STRATERGIES
TABLE 206.DANAHER CORPORATION: COMPANY SNAPSHOT
TABLE 207.DANAHER CORPORATION: OPERATING SEGMENTS
TABLE 208.DANAHER CORPORATION: PRODUCT PORTFOLIO
TABLE 209.DANAHER CORPORATION: NET SALES,
TABLE 210.DANAHER CORPORATION: KEY STRATERGIES

LIST OF FIGURES

FIGURE 1.GLOBAL SEPSIS DIAGNOSTIC MARKET SEGMENTATION
FIGURE 2.GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030
FIGURE 3.GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.GLOBAL SEPSIS DIAGNOSTIC MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11.GLOBAL SEPSIS DIAGNOSTIC MARKET,BY PRODUCT,2020(%)
FIGURE 12.COMPARATIVE SHARE ANALYSIS OF BLOOD CULTURE MEDIA GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF INSTRUMENTS GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ASSAY KITS & REAGENTS GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF SOFTWARE GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
FIGURE 16.GLOBAL SEPSIS DIAGNOSTIC MARKET,BY TECHNOLOGY,2020(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF MICROBIOLOGY GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF MOLECULAR DIAGNOSTICS GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF IMMUNOASSAYS GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF FLOW CYTOMETRY GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
FIGURE 21.GLOBAL SEPSIS DIAGNOSTIC MARKET,BY METHOD,2020(%)
FIGURE 22.COMPARATIVE SHARE ANALYSIS OF CONVENTIONAL DIAGNOSTICS GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
FIGURE 23.COMPARATIVE SHARE ANALYSIS OF AUTOMATED DIAGNOSTICS GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
FIGURE 24.GLOBAL SEPSIS DIAGNOSTIC MARKET,BY USABILITY,2020(%)
FIGURE 25.COMPARATIVE SHARE ANALYSIS OF LABORATORY TESTING GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
FIGURE 26.COMPARATIVE SHARE ANALYSIS OF POINT-OF-CARE TESTING GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
FIGURE 27.GLOBAL SEPSIS DIAGNOSTIC MARKET,BY PATHOGEN,2020(%)
FIGURE 28.COMPARATIVE SHARE ANALYSIS OF BACTERIAL SEPSIS GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
FIGURE 29.COMPARATIVE SHARE ANALYSIS OF FUNGAL SEPSIS GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
FIGURE 30.COMPARATIVE SHARE ANALYSIS OF OTHERS GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
FIGURE 31.GLOBAL SEPSIS DIAGNOSTIC MARKET BY REGION,2020
FIGURE 32.U.S. GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
FIGURE 33.CANADA GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
FIGURE 34.MEXICO GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
FIGURE 35.GERMANY GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
FIGURE 36.FRANCE GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
FIGURE 37.U.K. GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
FIGURE 38.ITALY GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
FIGURE 39.SPAIN GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
FIGURE 40.REST OF EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
FIGURE 41.JAPAN GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
FIGURE 42.CHINA GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
FIGURE 43.AUSTRALIA GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
FIGURE 44.INDIA GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
FIGURE 45.SOUTH KOREA GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
FIGURE 46.REST OF ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
FIGURE 47.BRAZIL GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
FIGURE 48.SAUDI ARABIA GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
FIGURE 49.SOUTH AFRICA GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
FIGURE 50.REST OF LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
FIGURE 51. TOP WINNING STRATEGIES, BY YEAR
FIGURE 52. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 53. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 54.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 55.COMPETITIVE DASHBOARD
FIGURE 56.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 57..: NET SALES ,($MILLION)
FIGURE 58.BIOMERIEUX SA.: NET SALES ,($MILLION)
FIGURE 59.THERMO FISHER SCIENTIFIC INC..: NET SALES ,($MILLION)
FIGURE 60.ABBOTT LABORATORIES, INC..: NET SALES ,($MILLION)
FIGURE 61.BECTON, DICKINSON AND COMPANY.: NET SALES ,($MILLION)
FIGURE 62.BRUKER CORPORATION.: NET SALES ,($MILLION)
FIGURE 63.BECKMAN COULTER, INC..: NET SALES ,($MILLION)
FIGURE 64.T2 BIOSYSTEMS, INC.: NET SALES ,($MILLION)
FIGURE 65.NANOSPHERE, INC..: NET SALES ,($MILLION)
FIGURE 66.HOFFMANN-LA ROCHE LTD.: NET SALES ,($MILLION)
FIGURE 67.DANAHER CORPORATION.: NET SALES ,($MILLION)

Product Code: A03908

The global sepsis diagnostic market valued at $569.49 million in 2020, and is estimated to reach $1207.58 million by 2030, growing at a CAGR of 7.8% from 2021 to 2030.

Sepsis is a life-threatening sickness that results from your body's immune system's response to an infection. Sepsis occurs when an existing infection causes the body's immune system to overreact. When an individual is sick, his/her immune system fights the infection by releasing proteins and other substances. When this response goes awry, it causes inflammation, which leads to sepsis. Bacterial infections are the most common cause of sepsis. Septic shock, a medical emergency, can result from severe sepsis. Septic shock is characterized by a fast drop in blood pressure, organ failure, and extensive tissue destruction. It can be lethal if left untreated.

The major factors that drive the growth of the global sepsis diagnostic market include increase in government funding for sepsis-related research activities and rise in prevalence of infectious diseases. In addition, increase in burden of sepsis and rise in global geriatric population propel the market growth. However, high cost of automated diagnostics devices is expected to impede the market growth. Conversely, development of rapid diagnosis/point-of-care techniques for early sepsis diagnostics is anticipated to provide lucrative opportunities to market players during the forecast period.The global sepsis diagnostic market is segmented into product type, technology, method, usability, pathogen, and region. According to product type, the market is categorized into blood culture media, instruments, assay kits & reagents, and software. By technology, it is segregated into microbiology, molecular diagnostics,immunoassays, and flow cytometry. On the basis of method, the market is categorized into conventional diagnostics and automated diagnostics. By usability, the market is bifurcated into laboratory testing and point-of-care testing. Depending on pathogen, the market is segregated into bacterial sepsis, fungal sepsis, and other pathogen. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA

The major companies profiled in the report include: Abbott Laboratories, Inc., Becton, Dickinson and Company, Bruker Corporation, BioMerieux, Beckman Coulter, Inc., Danaher Corporation, Nanosphere, Inc., Hoffmann-LA Roche Ltd., T2 Biosystems Inc., Thermo Fisher Scientific Inc.

Key Market Segments

By Method

Conventional Diagnostics
Automated Diagnostics

By Product

Blood Culture Media
Instruments
Assay kits Reagents
Software

By Technology

Microbiology
Molecular Diagnostics
Immunoassays
Flow Cytometry

By Usability

Laboratory Testing
Point-of-care Testing

By Pathogen

Bacterial Sepsis
Fungal Sepsis
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- BioMerieux SA
- Thermo Fisher Scientific Inc.
- Abbott Laboratories, Inc.
- Becton, Dickinson and Company
- Bruker Corporation
- Beckman Coulter, Inc.
- T2 Biosystems, Inc
- Nanosphere, Inc.
- Hoffmann-LA Roche Ltd
- Danaher Corporation

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings
- 3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT

4.1 Overview
- 4.1.1 Market size and forecast
4.2 Blood Culture Media
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
4.3 Instruments
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
4.4 Assay kits & Reagents
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
4.5 Software
- 4.5.1 Key market trends, growth factors and opportunities
- 4.5.2 Market size and forecast, by region
- 4.5.3 Market analysis by country

CHAPTER 5: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY

5.1 Overview
- 5.1.1 Market size and forecast
5.2 Microbiology
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
5.3 Molecular Diagnostics
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
5.4 Immunoassays
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
5.5 Flow Cytometry
- 5.5.1 Key market trends, growth factors and opportunities
- 5.5.2 Market size and forecast, by region
- 5.5.3 Market analysis by country

CHAPTER 6: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD

6.1 Overview
- 6.1.1 Market size and forecast
6.2 Conventional Diagnostics
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
6.3 Automated Diagnostics
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country

CHAPTER 7: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY

7.1 Overview
- 7.1.1 Market size and forecast
7.2 Laboratory Testing
- 7.2.1 Key market trends, growth factors and opportunities
- 7.2.2 Market size and forecast, by region
- 7.2.3 Market analysis by country
7.3 Point-of-care Testing
- 7.3.1 Key market trends, growth factors and opportunities
- 7.3.2 Market size and forecast, by region
- 7.3.3 Market analysis by country

CHAPTER 8: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN

8.1 Overview
- 8.1.1 Market size and forecast
8.2 Bacterial Sepsis
- 8.2.1 Key market trends, growth factors and opportunities
- 8.2.2 Market size and forecast, by region
- 8.2.3 Market analysis by country
8.3 Fungal Sepsis
- 8.3.1 Key market trends, growth factors and opportunities
- 8.3.2 Market size and forecast, by region
- 8.3.3 Market analysis by country
8.4 Others
- 8.4.1 Key market trends, growth factors and opportunities
- 8.4.2 Market size and forecast, by region
- 8.4.3 Market analysis by country

CHAPTER 9: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY REGION

9.1 Overview
- 9.1.1 Market size and forecast
9.2 North America
- 9.2.1 Key trends and opportunities
- 9.2.2 North America Market size and forecast, by Product
- 9.2.3 North America Market size and forecast, by Technology
- 9.2.4 North America Market size and forecast, by Method
- 9.2.5 North America Market size and forecast, by Usability
- 9.2.6 North America Market size and forecast, by Pathogen
- 9.2.7 North America Market size and forecast, by country
  - 9.2.7.1 U.S.
  - 9.2.7.1.1 Market size and forecast, by Product
  - 9.2.7.1.2 Market size and forecast, by Technology
  - 9.2.7.1.3 Market size and forecast, by Method
  - 9.2.7.1.4 Market size and forecast, by Usability
  - 9.2.7.1.5 Market size and forecast, by Pathogen
  - 9.2.7.2 Canada
  - 9.2.7.2.1 Market size and forecast, by Product
  - 9.2.7.2.2 Market size and forecast, by Technology
  - 9.2.7.2.3 Market size and forecast, by Method
  - 9.2.7.2.4 Market size and forecast, by Usability
  - 9.2.7.2.5 Market size and forecast, by Pathogen
  - 9.2.7.3 Mexico
  - 9.2.7.3.1 Market size and forecast, by Product
  - 9.2.7.3.2 Market size and forecast, by Technology
  - 9.2.7.3.3 Market size and forecast, by Method
  - 9.2.7.3.4 Market size and forecast, by Usability
  - 9.2.7.3.5 Market size and forecast, by Pathogen
9.3 Europe
- 9.3.1 Key trends and opportunities
- 9.3.2 Europe Market size and forecast, by Product
- 9.3.3 Europe Market size and forecast, by Technology
- 9.3.4 Europe Market size and forecast, by Method
- 9.3.5 Europe Market size and forecast, by Usability
- 9.3.6 Europe Market size and forecast, by Pathogen
- 9.3.7 Europe Market size and forecast, by country
  - 9.3.7.1 Germany
  - 9.3.7.1.1 Market size and forecast, by Product
  - 9.3.7.1.2 Market size and forecast, by Technology
  - 9.3.7.1.3 Market size and forecast, by Method
  - 9.3.7.1.4 Market size and forecast, by Usability
  - 9.3.7.1.5 Market size and forecast, by Pathogen
  - 9.3.7.2 France
  - 9.3.7.2.1 Market size and forecast, by Product
  - 9.3.7.2.2 Market size and forecast, by Technology
  - 9.3.7.2.3 Market size and forecast, by Method
  - 9.3.7.2.4 Market size and forecast, by Usability
  - 9.3.7.2.5 Market size and forecast, by Pathogen
  - 9.3.7.3 U.K.
  - 9.3.7.3.1 Market size and forecast, by Product
  - 9.3.7.3.2 Market size and forecast, by Technology
  - 9.3.7.3.3 Market size and forecast, by Method
  - 9.3.7.3.4 Market size and forecast, by Usability
  - 9.3.7.3.5 Market size and forecast, by Pathogen
  - 9.3.7.4 Italy
  - 9.3.7.4.1 Market size and forecast, by Product
  - 9.3.7.4.2 Market size and forecast, by Technology
  - 9.3.7.4.3 Market size and forecast, by Method
  - 9.3.7.4.4 Market size and forecast, by Usability
  - 9.3.7.4.5 Market size and forecast, by Pathogen
  - 9.3.7.5 Spain
  - 9.3.7.5.1 Market size and forecast, by Product
  - 9.3.7.5.2 Market size and forecast, by Technology
  - 9.3.7.5.3 Market size and forecast, by Method
  - 9.3.7.5.4 Market size and forecast, by Usability
  - 9.3.7.5.5 Market size and forecast, by Pathogen
  - 9.3.7.6 Rest of Europe
  - 9.3.7.6.1 Market size and forecast, by Product
  - 9.3.7.6.2 Market size and forecast, by Technology
  - 9.3.7.6.3 Market size and forecast, by Method
  - 9.3.7.6.4 Market size and forecast, by Usability
  - 9.3.7.6.5 Market size and forecast, by Pathogen
9.4 Asia-Pacific
- 9.4.1 Key trends and opportunities
- 9.4.2 Asia-Pacific Market size and forecast, by Product
- 9.4.3 Asia-Pacific Market size and forecast, by Technology
- 9.4.4 Asia-Pacific Market size and forecast, by Method
- 9.4.5 Asia-Pacific Market size and forecast, by Usability
- 9.4.6 Asia-Pacific Market size and forecast, by Pathogen
- 9.4.7 Asia-Pacific Market size and forecast, by country
  - 9.4.7.1 Japan
  - 9.4.7.1.1 Market size and forecast, by Product
  - 9.4.7.1.2 Market size and forecast, by Technology
  - 9.4.7.1.3 Market size and forecast, by Method
  - 9.4.7.1.4 Market size and forecast, by Usability
  - 9.4.7.1.5 Market size and forecast, by Pathogen
  - 9.4.7.2 China
  - 9.4.7.2.1 Market size and forecast, by Product
  - 9.4.7.2.2 Market size and forecast, by Technology
  - 9.4.7.2.3 Market size and forecast, by Method
  - 9.4.7.2.4 Market size and forecast, by Usability
  - 9.4.7.2.5 Market size and forecast, by Pathogen
  - 9.4.7.3 Australia
  - 9.4.7.3.1 Market size and forecast, by Product
  - 9.4.7.3.2 Market size and forecast, by Technology
  - 9.4.7.3.3 Market size and forecast, by Method
  - 9.4.7.3.4 Market size and forecast, by Usability
  - 9.4.7.3.5 Market size and forecast, by Pathogen
  - 9.4.7.4 India
  - 9.4.7.4.1 Market size and forecast, by Product
  - 9.4.7.4.2 Market size and forecast, by Technology
  - 9.4.7.4.3 Market size and forecast, by Method
  - 9.4.7.4.4 Market size and forecast, by Usability
  - 9.4.7.4.5 Market size and forecast, by Pathogen
  - 9.4.7.5 South Korea
  - 9.4.7.5.1 Market size and forecast, by Product
  - 9.4.7.5.2 Market size and forecast, by Technology
  - 9.4.7.5.3 Market size and forecast, by Method
  - 9.4.7.5.4 Market size and forecast, by Usability
  - 9.4.7.5.5 Market size and forecast, by Pathogen
  - 9.4.7.6 Rest of Asia-Pacific
  - 9.4.7.6.1 Market size and forecast, by Product
  - 9.4.7.6.2 Market size and forecast, by Technology
  - 9.4.7.6.3 Market size and forecast, by Method
  - 9.4.7.6.4 Market size and forecast, by Usability
  - 9.4.7.6.5 Market size and forecast, by Pathogen
9.5 LAMEA
- 9.5.1 Key trends and opportunities
- 9.5.2 LAMEA Market size and forecast, by Product
- 9.5.3 LAMEA Market size and forecast, by Technology
- 9.5.4 LAMEA Market size and forecast, by Method
- 9.5.5 LAMEA Market size and forecast, by Usability
- 9.5.6 LAMEA Market size and forecast, by Pathogen
- 9.5.7 LAMEA Market size and forecast, by country
  - 9.5.7.1 Brazil
  - 9.5.7.1.1 Market size and forecast, by Product
  - 9.5.7.1.2 Market size and forecast, by Technology
  - 9.5.7.1.3 Market size and forecast, by Method
  - 9.5.7.1.4 Market size and forecast, by Usability
  - 9.5.7.1.5 Market size and forecast, by Pathogen
  - 9.5.7.2 Saudi Arabia
  - 9.5.7.2.1 Market size and forecast, by Product
  - 9.5.7.2.2 Market size and forecast, by Technology
  - 9.5.7.2.3 Market size and forecast, by Method
  - 9.5.7.2.4 Market size and forecast, by Usability
  - 9.5.7.2.5 Market size and forecast, by Pathogen
  - 9.5.7.3 South Africa
  - 9.5.7.3.1 Market size and forecast, by Product
  - 9.5.7.3.2 Market size and forecast, by Technology
  - 9.5.7.3.3 Market size and forecast, by Method
  - 9.5.7.3.4 Market size and forecast, by Usability
  - 9.5.7.3.5 Market size and forecast, by Pathogen
  - 9.5.7.4 Rest of LAMEA
  - 9.5.7.4.1 Market size and forecast, by Product
  - 9.5.7.4.2 Market size and forecast, by Technology
  - 9.5.7.4.3 Market size and forecast, by Method
  - 9.5.7.4.4 Market size and forecast, by Usability
  - 9.5.7.4.5 Market size and forecast, by Pathogen

CHAPTER 10: COMPANY LANDSCAPE

10.1. Introduction
10.2. Top winning strategies
10.3. Product Mapping of Top 10 Player
10.4. Competitive Dashboard
10.5. Competitive Heatmap
10.6. Key developments

CHAPTER 11: COMPANY PROFILES

11.1

11.1.1 Company overview
11.1.2 Company snapshot
11.1.3 Operating business segments
11.1.4 Product portfolio
11.1.5 Business performance
11.1.6 Key strategic moves and developments

11.2 BioMerieux SA
- 11.2.1 Company overview
- 11.2.2 Company snapshot
- 11.2.3 Operating business segments
- 11.2.4 Product portfolio
- 11.2.5 Business performance
- 11.2.6 Key strategic moves and developments
11.3 Thermo Fisher Scientific Inc.
- 11.3.1 Company overview
- 11.3.2 Company snapshot
- 11.3.3 Operating business segments
- 11.3.4 Product portfolio
- 11.3.5 Business performance
- 11.3.6 Key strategic moves and developments
11.4 Abbott Laboratories, Inc.
- 11.4.1 Company overview
- 11.4.2 Company snapshot
- 11.4.3 Operating business segments
- 11.4.4 Product portfolio
- 11.4.5 Business performance
- 11.4.6 Key strategic moves and developments
11.5 Becton, Dickinson and Company
- 11.5.1 Company overview
- 11.5.2 Company snapshot
- 11.5.3 Operating business segments
- 11.5.4 Product portfolio
- 11.5.5 Business performance
- 11.5.6 Key strategic moves and developments
11.6 Bruker Corporation
- 11.6.1 Company overview
- 11.6.2 Company snapshot
- 11.6.3 Operating business segments
- 11.6.4 Product portfolio
- 11.6.5 Business performance
- 11.6.6 Key strategic moves and developments
11.7 Beckman Coulter, Inc.
- 11.7.1 Company overview
- 11.7.2 Company snapshot
- 11.7.3 Operating business segments
- 11.7.4 Product portfolio
- 11.7.5 Business performance
- 11.7.6 Key strategic moves and developments
11.8 T2 Biosystems, Inc
- 11.8.1 Company overview
- 11.8.2 Company snapshot
- 11.8.3 Operating business segments
- 11.8.4 Product portfolio
- 11.8.5 Business performance
- 11.8.6 Key strategic moves and developments
11.9 Nanosphere, Inc.
- 11.9.1 Company overview
- 11.9.2 Company snapshot
- 11.9.3 Operating business segments
- 11.9.4 Product portfolio
- 11.9.5 Business performance
- 11.9.6 Key strategic moves and developments
11.10 Hoffmann-LA Roche Ltd
- 11.10.1 Company overview
- 11.10.2 Company snapshot
- 11.10.3 Operating business segments
- 11.10.4 Product portfolio
- 11.10.5 Business performance
- 11.10.6 Key strategic moves and developments
11.11 Danaher Corporation
- 11.11.1 Company overview
- 11.11.2 Company snapshot
- 11.11.3 Operating business segments
- 11.11.4 Product portfolio
- 11.11.5 Business performance
- 11.11.6 Key strategic moves and developments

敗血症診断の世界市場 - 市場機会分析および産業予測：製品別、技術別、手法別、使用別、病原体別（2020年～2030年）

Global Sepsis Diagnostic Market By Product, By Technology, By Method, By Usability, By Pathogen : Global Opportunity Analysis and Industry Forecast, 2020-2030

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章世界の敗血症診断市場：製品別

第5章世界の敗血症診断市場：技術別

第6章世界の敗血症診断市場：手法別

第7章世界の敗血症診断市場：使用別

第8章世界の敗血症診断市場：病原体別

第9章世界の敗血症診断市場：地域別

第10章企業情勢

第11章企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Market Segments

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

CHAPTER 2:EXECUTIVE SUMMARY

CHAPTER 3:MARKET OVERVIEW

CHAPTER 4: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT

CHAPTER 5: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY

CHAPTER 6: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD

CHAPTER 7: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY

CHAPTER 8: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN

CHAPTER 9: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY REGION

CHAPTER 10: COMPANY LANDSCAPE

CHAPTER 11: COMPANY PROFILES

敗血症診断の世界市場 - 市場機会分析および産業予測：製品別、技術別、手法別、使用別、病原体別（2020年～2030年）

Global Sepsis Diagnostic Market By Product, By Technology, By Method, By Usability, By Pathogen : Global Opportunity Analysis and Industry Forecast, 2020-2030

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

第4章 世界の敗血症診断市場：製品別

第5章 世界の敗血症診断市場：技術別

第6章 世界の敗血症診断市場：手法別

第7章 世界の敗血症診断市場：使用別

第8章 世界の敗血症診断市場：病原体別

第9章 世界の敗血症診断市場：地域別

第10章 企業情勢

第11章 企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Market Segments

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

CHAPTER 2:EXECUTIVE SUMMARY

CHAPTER 3:MARKET OVERVIEW

CHAPTER 4: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT

CHAPTER 5: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY

CHAPTER 6: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD

CHAPTER 7: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY

CHAPTER 8: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN

CHAPTER 9: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY REGION

CHAPTER 10: COMPANY LANDSCAPE

CHAPTER 11: COMPANY PROFILES

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章世界の敗血症診断市場：製品別

第5章世界の敗血症診断市場：技術別

第6章世界の敗血症診断市場：手法別

第7章世界の敗血症診断市場：使用別

第8章世界の敗血症診断市場：病原体別

第9章世界の敗血症診断市場：地域別

第10章企業情勢

第11章企業プロファイル